Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebroventricular Administration of A-dopamine for Severe Motor Fluctuations in Parkinson's Disease
NCT04332276Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Sep 2020
- Primary completion
- May 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of A-dopamine in Parkinson's disease (PD), sponsored by CHU de Lille. Started Sep 2020; status: completed.
02
Drugs
A-dopamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04332276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332276.